XOMA Jun 2024 17.500 call
| Previous Close | 7.50 |
| Open | 7.50 |
| Bid | 5.90 |
| Ask | 10.00 |
| Strike | 17.50 |
| Expire Date | 2024-06-21 |
| Day's Range | 7.50 - 7.50 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 5 |
GlobeNewswireXOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher
EMERYVILLE, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has received an $8.1 million milestone payment from Viracta Therapeutics, Inc., related to Day One Biopharmaceuticals’ recent sale of its Priority Review Voucher (PRV) for $108 million to an undisclosed buyer. “OJEMDA™ offers patients six months of age and older who have relapsed or refractory BRAF-altered pediatric low-grade glioma (pLGG) the only approved th
- GlobeNewswire
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that members of its Executive Team will participate in the H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ being held on May 20, 2024, in New York, NY. Owen Hughes, Chief Executive Officer, and Brad Sitko, Chief Investment Officer, will be featured in a fireside chat taking place at 11:00 AM ET. The presentation can be accessed at https://bit.l
GuruFocus.comXOMA Corp (XOMA) Q1 2024 Earnings: Misses Revenue Estimates, Reports Lower Net Loss
Comprehensive Analysis of XOMA's Financial Performance and Strategic Highlights
